Even worse, LP has 139 million share and share equivalents (options, warrants). She has a significant vested interest in success which is why the failed original trial is not a manipulated trial with new protocol, primary endpoint, comparator and SAP. Even added a recurrent GBM arm that was NOT part of the original trial protocol,
She's desperate to salvage the trial to save her net worth. But you notice that many shareholders didn't buy it as share price, down >50% in 52 weeks AFTER the TLD data was released. If she started selling shares, it is likely many other shareholders would head for the exits too.
But the next round of financing should be very interesting as they are down to vulture funding or dilution. Another zombie biotech.